title: Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy.
abstract: MEK1 (MAP2K1) and MEK2 (MAP2K2) are closely related dual-specificity protein kinases which function by phosphorylating both serine/threonine and tyrosine residues of their substrates ERK1 and ERK2, controlling fundamental cellular processes that include cell growth and proliferation. To investigate the prognostic significance of pMEK expression in the nucleus and cytoplasm among patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy.
  
  
  
  Immunohistochemistry was performed on the retrieved archival tissue of 96 patients to detect pMEK, p53 and Ki-67.
  
  
  
  Sixty-six percent of patients were positive for pMEK expression in the nucleus and 41 % in cytoplasm. On univariate analysis, high nuclear pMEK was predictive of worse 5y-DFS and 5y-OS, with a trend to significance (26 % vs. 41 %, p = 0.09; 36 % vs. 47 %, p = 0.07). High cytoplasmic pMEK was predictive of better 5-y OS and 5-y DFS outcomes (61 % vs. 27 %, p = 0.01; 46 % vs. 22 %, p = 0.02). On multivariate analysis, low cytoplasmic pMEK and high nuclear pMEK predicted worse DFS and OS (p = 0.01; p = 0.04 and p = 0.02; p = 0.02 respectively).
  
  
  
  Subcellular localisation of pMEK has different prognosis in locally advanced head and neck cancer treated with radiochemotherapy.
authors: Radiation Oncology Department, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n, 29010, Malaga, Spain. jaimegomezmillan@gmail.com.
authors: J
authors: J
authors: Gomez-Millan
authors: Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n, 29010, Malaga, Spain. bellapajares@yahoo.es.
authors: B
authors: B
authors: Pajares
authors: Pathology Department, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n, 29010, Malaga, Spain.
authors: L
authors: L
authors: Perez-Villa
authors: Instituto de Biomedicina de Sevilla (IBIS), Consejo superior de investigaciones científicas, Campus Universitario Virgen del Rocío, Avda, Manuel Siurot s/n, 41013, Sevilla, Spain.
authors: A
authors: A
authors: Carnero
authors: Pathology Department, Facultad de Medicina, UMA, Campus Teatinos s/n, 29010, Malaga, Spain.
authors: M
authors: M
authors: Alvarez
authors: Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n, 29010, Malaga, Spain.
authors: V
authors: V
authors: De Luque
authors: Agencia Sanitaria Costa del Sol, Unidad de Investigación, Autovia A-7, Km 187, 29063, Marbella, Málaga, Spain.|Red Nacional de Investigación de Servicios de Salud en Enfermedades crónicas (REDISSEC), Madrid, Spain.
authors: F
authors: F
authors: Rivas
authors: Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n, 29010, Malaga, Spain.
authors: J M
authors: JM
authors: Trigo
authors: Radiation Oncology Department, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n, 29010, Malaga, Spain.
authors: M D
authors: MD
authors: Toledo
authors: Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n, 29010, Malaga, Spain.
authors: E
authors: E
authors: Alba
authors: Radiation Oncology Department, Hospital Universitario Virgen de la Victoria, Campus Teatinos s/n, 29010, Malaga, Spain.
authors: J A
authors: JA
authors: Medina
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D059248:Chemoradiotherapy; D048049:Extracellular Signal-Regulated MAP Kinases / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015870:Gene Expression; D006258:Head and Neck Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010766:Phosphorylation; D011379:Prognosis; D021381:Protein Transport; D012307:Risk Factors; D015398:Signal Transduction
chemical_list: D015415:Biomarkers; D048049:Extracellular Signal-Regulated MAP Kinases
keywords: Head and neck cancer; Radiochemotherapy; pMEK